Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Lilly is also running two other trials with eloralintide plus tirzepatide, including another mid-stage study in obese and overweight type 2 diabetes patients, with an initial completion date in June 2026, and a Phase I trial in nondiabetic individuals, scheduled to complete in October 2025
Recent Findings Type 2 diabetes treatment with GLP-1RA liraglutide and semaglutide paved way to a ground-breaking therapy specific for obesity, as shown with the SCALE 3 mg/day liraglutide program and the STEP 2.4 mg/week semaglutide program
This two-pronged approach enhances GLP-1 activity and also influences gene expression to keep everything running smoothly
Frhlich H, Kollmeyer ML, Linz VC, Stuhlinger M, Groneberg D, Reigl A, Zizer E, Friebe A, Niesler B, Rappold G
Eryptosis in health and disease: a paradigm shift towards understanding the (patho)physiological implications of programmed cell death of erythrocytes
Key Features Dual-mechanism design: GHRH-receptor agonism (CJC-1295) + GHSR agonism (Ipamorelin) for complementary GH-axis interrogation 99% Purity (HPLC/MS verified): Consistent material for reproducible protocols Protocol-friendly kinetics: Short, high-amplitude GH pulse (Ipamorelin) alongside prolonged GH/IGF-1 support (CJC-1295) in model systems GMP-compliant manufacturing (USA): Batch-to-batch reliability COA included: Full lot documentation Specifications Identity: CJC-1295 NO DAC /Ipamorelin USA cGMP Produced Form & Sizes: 10 mg or 20 mg blended vials Appearance: White to off-white lyophilized powder Purity: 99% (HPLC/MS verified) Manufacturing: GMP-compliant facility, USA Storage: 20 C, desiccated
US$ 28.73
US$ 22.95
US$ 27.27
US$ 23.16
US$ 23.87
